Show simple item record

dc.contributor.authorGeorgakis, Marios K.
dc.contributor.authorMalik, Rainer
dc.contributor.authorBjörkbacka, Harry
dc.contributor.authorPana, Tiberiu A
dc.contributor.authorDemissie, Serkalem
dc.contributor.authorAyers, Colby
dc.contributor.authorElhadad, Mohamed A.
dc.contributor.authorFornage, Myriam
dc.contributor.authorBeiser, Alexa
dc.contributor.authorBenjamin, Emelia J.
dc.contributor.authorBoekholdt, S Matthijs
dc.contributor.authorEngström, Gunnar
dc.contributor.authorHerder, Christian
dc.contributor.authorHoogeveen, Ron C.
dc.contributor.authorKoenig, Wolfgang
dc.contributor.authorMelander, Olle
dc.contributor.authorOrho-Melander, Marju
dc.contributor.authorSchiopu, Alexandru
dc.contributor.authorSöderholm, Martin
dc.contributor.authorWareham, Nick
dc.contributor.authorBallantyne, Christie M.
dc.contributor.authorPeters, Annette
dc.contributor.authorSeshadri, Sudha
dc.contributor.authorMyint, Phyo Kyaw
dc.contributor.authorNilsson, Jan
dc.contributor.authorde Lemos, James A.
dc.contributor.authorDichgans, Martin
dc.date.accessioned2020-03-03T00:02:40Z
dc.date.available2020-03-03T00:02:40Z
dc.date.issued2019-09-27
dc.identifier147240953
dc.identifieraaa2e72a-409b-4afd-b3eb-45828692664b
dc.identifier31476962
dc.identifier85072718369
dc.identifier.citationGeorgakis , M K , Malik , R , Björkbacka , H , Pana , T A , Demissie , S , Ayers , C , Elhadad , M A , Fornage , M , Beiser , A , Benjamin , E J , Boekholdt , S M , Engström , G , Herder , C , Hoogeveen , R C , Koenig , W , Melander , O , Orho-Melander , M , Schiopu , A , Söderholm , M , Wareham , N , Ballantyne , C M , Peters , A , Seshadri , S , Myint , P K , Nilsson , J , de Lemos , J A & Dichgans , M 2019 , ' Circulating monocyte chemoattractant protein-1 and risk of stroke : Meta-Analysis of Population-Based Studies Involving 17 180 Individuals ' , Circulation Research , vol. 125 , no. 8 , pp. 773-782 . https://doi.org/10.1161/CIRCRESAHA.119.315380en
dc.identifier.issn0009-7330
dc.identifier.otherMendeley: d1072815-19de-32e2-8fa3-62869a0d0980
dc.identifier.otherORCID: /0000-0002-1423-8111/work/96652726
dc.identifier.urihttps://hdl.handle.net/2164/13769
dc.descriptionM. Georgakis is funded by scholarships from the German Academic Exchange Service (DAAD) and Onassis Foundation. The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). The DHS study was funded by a grant from the Donald W. Reynolds Foundation. The EPIC-Norfolk study is funded by grants from the Medical Research Council UK (G9502233, G0401527) and Cancer Research UK (C864/A8257, C864/A2883). FHS is supported by the National Heart, Lung and Blood Institute’s Framingham Heart Study (Contract No. N01-HC-25195 and No. HHSN268201500001I and 75N92019D00031), received funding by grants from the National Institute of Aging (R01s AG054076, AG049607, AG059421, U01-AG049505, AG058589 and AG052409) and the National Institute of Neurological Disorders and Stroke (R01 NS017950, UH2 NS100605), as well as grants for the MCP-1 measurements by NIH (1RO1 HL64753, R01 HL076784, 1 R01 AG028321). The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. The MDCS-CV study has been supported with funding from the Swedish Research Council, Swedish Heart and Lung Foundations, and the Swedish Foundation for Strategic Research. This project has received funding from the European Union’s Horizon 2020 research and innovation programme (No 666881), SVDs@target (to M. Dichgans) and No 667375, CoSTREAM (to M. Dichgans); the DFG as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198) and the CRC 1123 (B3) (to M. Dichgans); the Corona Foundation (to M. Dichgans); the Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain)(to M. Dichgans); the e:Med program (e:AtheroSysMed) (to M. Dichgans) and the FP7/2007-2103 European Union project CVgenes@target (grant agreement number Health-F2-2013-601456) (to M. Dichgans). The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.en
dc.format.extent10
dc.format.extent411474
dc.format.extent327808
dc.format.extent105702
dc.format.extent189520
dc.format.extent514819
dc.language.isoeng
dc.relation.ispartofCirculation Researchen
dc.subjectmonocyte chemoattractant protein-1en
dc.subjectCCL2en
dc.subjectstrokeen
dc.subjectcerebrovascular diseaseen
dc.subjectatherosclerosisen
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleCirculating monocyte chemoattractant protein-1 and risk of stroke : Meta-Analysis of Population-Based Studies Involving 17 180 Individualsen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doi10.1161/CIRCRESAHA.119.315380
dc.date.embargoedUntil2020-03-03
dc.identifier.urlhttp://www.mendeley.com/research/circulating-monocyte-chemoattractant-protein1-risk-stroke-metaanalysis-populationbased-studies-involen


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record